The latest headlines across every section, pulled from official and open-access sources.
Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savings program anchored in its new five-year strategic plan. But to CEO Naoki Okamura, “it’s not simply saving the cost or reducing the headcount.”
As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
Novartis has reported a phase 1/2 win for one of the jewels of its $12 billion Avidity Biosciences buyout, setting the Swiss drugmaker up to talk to global regulatory agencies about the next steps for its dystrophy prospect.
Over-the-counter drugmaker Perrigo Company is washing its hands of chief executive Patrick Lockwood-Taylor, who resigned from his post of president and CEO after the company’s board of directors found “certain personal conduct” by Lockwood-Taylor inconsistent with its code of conduct and “core values.” Board member Albert Manzone is stepping up to replace the CEO in the interim as the board searches for a permanent successor.
Boehringer Ingelheim’s Hernexeos has nabbed a companion diagnostic from Guardant Health after the FDA cleared its liquid biopsy test, Guardant360 CDx.
Christelle Huguet, Ph.D., Ipsen’s executive vice president and head of R&D, sits down with Fierce Healthcare & Life Sciences Editor-in-Chief Ayla Ellison to discuss pipeline discipline, external partnerships and key 2026 milestones.
Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own record-breaker this week.
Patients who underwent mitral transcatheter edge-to-edge repair (M-TEER) with an optimal result were more likely to have improved hemodynamics and less likely to experience major adverse events, all-cause mortality, heart failure (HF) hospitalization or reintervention at one year...
This episode provides a team-based overview of diagnosing and managing acute paroxysmal supraventricular tachycardia (PSVT) across care settings.
Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma giant made the bet.
Neoantigen-based therapies are considered one of the most promising approaches in modern immuno-oncology. One challenge continues to limit the field: accurately identifying which neoantigens will generate meaningful anti-tumor immunity.
Soligenix has scrapped its cutaneous T-cell lymphoma program in the wake of a phase 3 setback, leaving the biotech focused on another rare disease prospect and considering strategic alternatives.
New office will coordinate efforts to develop, validate and scale animal-free research models.
U.K. regulators have issued a “negative review” of Traws Pharma’s planned human influenza challenge study, forcing the biotech to defer a phase 2a trial tied to $20 million in funding.
Neumora's navacaprant has completed a clean sweep of trial misses in major depressive disorder.
Six weeks after Intellia Therapeutics reported that it met its primary endpoint in a phase 3 trial of its in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) for patients with hereditary angioedema (HAE), the company released additional positive data showing that the study also met its secondary endpoints with statistical and clinical significance.
A federal jury in Delaware has found that Amgen and its acquired Teneobio willfully infringed on an antibody patent held by Harbour Antibodies, a Dutch subsidiary of China’s Harbour BioMed.
With Johnson & Johnson gradually fleshing out its $55 billion U.S. investment scheme in recent months, the New Jersey-headquartered drug and medical device giant on Monday revealed just how the plan will benefit its medtech operations, specifically in the field of vision care.
NIH-supported, long-term clinical trial found no difference between metformin and placebo.
The ACC submitted comments to the Centers for Medicare and Medicaid Services (CMS) regarding the fiscal year 2027 Inpatient Prospective Payment System (IPPS) proposed rule.
Survodutide led to significant weight loss in adults with obesity and without diabetes, according to results from the randomized, placebo-controlled SYNCHRONIZE-1 trial published June 7 in NEJM.
Nature Index’s latest research rankings show that China continues to be the clear leader in contributions to scientific journals, with a 22% increase between 2024 and 2025. While China remains well ahead of the rest of the top 10, nearly 10% growth in journal contributions from Japan and South Korea outpaced higher-ranked Western countries such as the U.S., Germany and the U.K.
The company's SPY002 prompted a 10.7-point reduction from baseline levels in patients’ Robart’s Histopathology Index (RHI) scores by week 12.
Executives told Fierce how the company is in the middle of a transition to “the new Biogen”—embracing partnerships, investment and entrepreneurship to replenish its pipeline.